These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 4701794

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R, Gretenkort Andersson N.
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ, Obaji SG, Collins PW.
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prophylactic factor replacement in hemophilia.
    Carcao MD, Aledort L.
    Blood Rev; 2004 Jun; 18(2):101-13. PubMed ID: 15010149
    [Abstract] [Full Text] [Related]

  • 12. How to manage invasive procedures in children with haemophilia.
    Ljung RC, Knobe K.
    Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
    Collins P, Chalmers E, Chowdary P, Keeling D, Mathias M, O'Donnell J, Pasi KJ, Rangarajan S, Thomas A.
    Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
    [Abstract] [Full Text] [Related]

  • 17. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M.
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [Abstract] [Full Text] [Related]

  • 18. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D, Rodgers GM.
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract] [Full Text] [Related]

  • 19. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M, Shirahata A.
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [Abstract] [Full Text] [Related]

  • 20. Epsilon-Aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial.
    Walsh PN, Rizza CR, Matthews JM, Eipe J, Kernoff PB, Coles MD, Bloom AL, Kaufman BM, Beck P, Hanan CM, Biggs R.
    Br J Haematol; 1971 May; 20(5):463-75. PubMed ID: 4931484
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.